ABSTRACT NUMBER: ESOC2026A1680 EVALUATION OF SINGLE CHAIN AND TWO CHAIN ALTEPLASE AND TENECTEPLASE AND COMPARISON OF TNK FORMULATIONS

Abstract Background and aims Alteplase is produced as a single chain enzyme but is converted into a more active two-chain form by plasmin. Tenecteplase is structurally similar to alteplase and shows higher resistance to PAI-1. Factors influencing two-chain conversion of tenecteplase are poorly understood. Several formulations of TNK are now available. We compared two-chain conversion of alteplase and four tenecteplase formulations and downstream consequences on plasminogen activation, fibrinogenolysis, and PAI-1 resistance. Methods Alteplase and four tenecteplase formulations: Metalyse (Boehringer Ingelheim), Tenectase (Gennova, India), Mingfule (CSPC, China), GenetPA (BioApower, China) were compared. Two-chain conversion was achieved with plasmin and by western blotting. Proteolytic activity and the effect of PAI-1 was evaluated using amidolytic or fibrinolysis assays. Results Plasmin caused a dose-dependent conversion of alteplase and all tenecteplase formulations into their two-chain forms resulting in a ~2.5-fold increase in proteolytic activity. Two-chain conversion of alteplase, but not tenecteplase, occurred in plasma coinciding with off-target fibrinogen depletion. Metalyse contained ~3-fold more two-chain tenecteplase compared to other formulations, resulting in higher proteolytic activity in the absence of fibrin. However, all tenecteplase formulations showed similar activity in their two-chain form. Two-chain conversion of all tenecteplase formulations increased PAI-1 binding and a significant decrease in PAI-1 resistance. Conclusions Generation of two-chain tPA promotes fibrinogenolysis. Metalyse contains 3-fold more two-chain species and is more active in the absence of fibrin than other tenecteplase formulations. However, all tenecteplase formulations have similar proteolytic activity in their two-chain form but lose some resistance to PAI-1. Conflict of interest Liu: Nothing to disclose; Tippett: Nothing to disclose; McCutcheon: Nothing to disclose; Keragala: Nothing to disclose; Lin: Nothing to disclose; Xiong: Nothing to disclose; Wang: Nothing to disclose; Campbell: Nothing to disclose; Parsons: Nothing to disclose; Medcalf: Nothing to disclose

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.794
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A1680 EVALUATION OF SINGLE CHAIN AND TWO CHAIN ALTEPLASE AND TENECTEPLASE AND COMPARISON OF TNK FORMULATIONS

Yunyun Xiong, Zikou Liu, Bruce C.V. Campbell, Isabel Tippett et al.
European Stroke Journal
Protease and Inhibitor Mechanisms
article

ABSTRACT NUMBER: ESOC2026A1680 EVALUATION OF SINGLE CHAIN AND TWO CHAIN ALTEPLASE AND TENECTEPLASE AND COMPARISON OF TNK FORMULATIONS

Yunyun Xiong, Zikou Liu, Bruce C.V. Campbell, Isabel Tippett, Mark Parsons, Charithani Keragala, Fiona McCutcheon, Robert Medcalf, Yongjun Wang, Longting Lin
article en

Abstract

Abstract Background and aims Alteplase is produced as a single chain enzyme but is converted into a more active two-chain form by plasmin. Tenecteplase is structurally similar to alteplase and shows higher resistance to PAI-1. Factors influencing two-chain conversion of tenecteplase are poorly understood. Several formulations of TNK are now available. We compared two-chain conversion of alteplase and four tenecteplase formulations and downstream consequences on plasminogen activation, fibrinogenolysis, and PAI-1 resistance. Methods Alteplase and four tenecteplase formulations: Metalyse (Boehringer Ingelheim), Tenectase (Gennova, India), Mingfule (CSPC, China), GenetPA (BioApower, China) were compared. Two-chain conversion was achieved with plasmin and by western blotting. Proteolytic activity and the effect of PAI-1 was evaluated using amidolytic or fibrinolysis assays. Results Plasmin caused a dose-dependent conversion of alteplase and all tenecteplase formulations into their two-chain forms resulting in a ~2.5-fold increase in proteolytic activity. Two-chain conversion of alteplase, but not tenecteplase, occurred in plasma coinciding with off-target fibrinogen depletion. Metalyse contained ~3-fold more two-chain tenecteplase compared to other formulations, resulting in higher proteolytic activity in the absence of fibrin. However, all tenecteplase formulations showed similar activity in their two-chain form. Two-chain conversion of all tenecteplase formulations increased PAI-1 binding and a significant decrease in PAI-1 resistance. Conclusions Generation of two-chain tPA promotes fibrinogenolysis. Metalyse contains 3-fold more two-chain species and is more active in the absence of fibrin than other tenecteplase formulations. However, all tenecteplase formulations have similar proteolytic activity in their two-chain form but lose some resistance to PAI-1. Conflict of interest Liu: Nothing to disclose; Tippett: Nothing to disclose; McCutcheon: Nothing to disclose; Keragala: Nothing to disclose; Lin: Nothing to disclose; Xiong: Nothing to disclose; Wang: Nothing to disclose; Campbell: Nothing to disclose; Parsons: Nothing to disclose; Medcalf: Nothing to disclose

European Stroke JournalVol. 11(Supplement_1)
The University of Melbourne (AU), UNSW Sydney (AU), Beijing Tian Tan Hospital (CN), Monash University (AU)
Openalex Percentile: Top 9%
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.